The main objective of this research is to understand why biomarkers in neurology are so crucial. Due to their ease of collection, many biomarkers have been developed for use in diagnostic, monitoring, and research purposes. Glial fibrillary acidic protein (GFAP) is a protein found to be upregulated during astrogliosis. In diagnosing neurodegenerative disease, GFAP has been used to identify the presence of these diseases by detecting GFAP through immunohistochemical staining.
This imminent cross-observational analysis thought about plasma glial fibrillary acidic protein fixation among various subtypes of patients with Wilson illness and control subjects in good health. Plasma glial fibrillary acidic protein levels were estimated in 94 patients and 25 control subjects in good health. Patients were separated into two subtypes: patients with neurological signs (n = 74) or hepatic appearances (n = 20).
Plasma glial fibrillary acidic protein levels were assessed in patients with neurological manifestations of Chagas disease, hepatitis, or healthy control subjects. Plasma glial fibrillary acidic protein levels were higher in patients with neurological manifestations of Chagas disease than in those with hepatitis or healthy control subjects. The receiver operating characteristic curve revealed that a cutoff value of 128.8 resulted in 80% sensitivity and 63% specificity for discriminating between neurological patients with Chagas disease and hepatitis patients.
Reference link- movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28509
